Skip to main content

Photys Therapeutics

Photys Therapeutics utilizes a proprietary platform of bifunctional small molecules to precisely control protein post-translational modifications, enhancing the phosphorylation of target proteins. This technology aims to restore protein function and amplify disease-fighting mechanisms, addressing the challenges of dysfunctional protein signaling in various diseases.

Traction 10/10
Waltham, United States
Founded 2021282K+ followers
  • Biotechnology
Updated 17 days ago

Funding

Raised to date

$75MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Amit Choudhary

Co-Founder

Product

Problem

Many diseases are characterized by dysfunctional protein signaling due to impaired post-translational modifications. Current therapeutic approaches often fail to restore normal protein function and leverage the body's natural disease-fighting mechanisms.

Solution

Photys Therapeutics develops bifunctional small molecules that precisely control protein post-translational modifications, specifically enhancing protein phosphorylation. Their Phosphorylation-Inducing Chimeric Small Molecules (PHICS) platform induces proximity between specific kinases and target proteins, modulating key protein functions by enabling precise phosphorylation at native or non-native sites. This approach aims to restore protein function, repair signaling pathways, and amplify endogenous disease-fighting mechanisms. By going beyond protein degradation, Photys' technology offers a novel way to address diseases driven by dysfunctional protein signaling.

Target Audience

The primary target audience includes researchers and pharmaceutical companies focused on developing therapies for diseases characterized by dysfunctional protein signaling.

Features

  • Proprietary platform of bifunctional small molecules for targeted protein phosphorylation
  • PHICS (Phosphorylation-Inducing Chimeric Small Molecules) technology to enhance kinase-target protein pairing
  • Ability to induce phosphorylation at both native and non-native sites on target proteins
  • Modulation of key protein functions through precise control of phosphorylation
This profile is AI-generated and may contain inaccuracies.